In WHO Useful Class II patients, look at whether the key benefits of bosentan are sufficient to offset the chance of hepatotoxicity, which can preclude long run use as their disorder progresses.Identify your selection: Identify has to be fewer than figures Opt for a group: Unable to load your selection as a consequence of an errorFor anyone who is